Diligence memo · auto-generated · as of July 2, 2026

ValCor Cath Inc.

ValCor Cath Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

ValCor Cath Inc. operates in Biotechnology, based in OTTAWA HILLS.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

ValCor Cath Inc. has raised $4.3M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $4.3M on 2023-05-19.

Most recent recorded round closed around 2023-05-19.

Valuation (modeled)modeled

Provath models ValCor Cath Inc. at approximately $38M (range $4.6M–$107M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.86× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era. Within the normal band (86% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 3.1 yr ago; this sector typically re-raises about every 14 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 40% of Biotechnology peers (4293 compared).

Modeled value ranks above 40% of those peers.

Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.